PAN-EUROPEAN REAL-WORLD EXPERIENCE WITH PERAMPANEL: RATIONALE, DESIGN, AND PRELIMINARY DATA FROM POOLED OBSERVATIONAL STUDIES ACROSS EUROPE

被引：0
|
作者：
Trinka, E. [1 ]
Zimmermann, G. [1 ,2 ,3 ]
Rohracher, A. [1 ]
Shankar, R. [4 ]
Sander, J. [5 ]
Brodie, M. J. [6 ]
Garamendi, I [7 ]
Wehner, T. [8 ]
McLean, B. [9 ]
Mohan, M. [10 ]
Pace, A. [11 ]
Sadler, M. [12 ]
Wiggans, C. [4 ]
Stephen, L. [6 ]
Di Gennaro, G. [13 ]
de Toffol, B. [14 ,15 ]
Crespel, A. [16 ]
Marousset, A. [14 ,15 ]
Menzler, K. [17 ]
Knake, S. [17 ]
Bertol-Alegre, V [18 ]
Garcia-Morales, I [19 ]
de Toledo-Heras, M. [20 ]
Marinas-Alejo, A. [7 ]
机构：
[1] Paracelsus Med Univ, Dept Neurol, Christian Doppler Klin, Salzburg, Austria
[2] Paracelsus Med Univ, Spinal Cord Injury & Tissue Regenerat Ctr, Salzburg, Austria
[3] Paris Lodron Univ, Dept Math, Salzburg, Austria
[4] Cornwall Partnership NHS Fdn Trust, Exeter, Devon, England
[5] Inst Neurol, London, England
[6] West Glasgow ACH Yorkhill, Glasgow, Lanark, Scotland
[7] Hosp Univ Cruces, Baracaldo, Spain
[8] Natl Hosp Neurol & Neurosurg, London, England
[9] Royal Cornwall Hosp, Truro, England
[10] North Bristol NHS Trust, Bristol, Avon, England
[11] Salford Royal Fdn Trust, Salford, Lancs, England
[12] Plymouth Hosp NHS Trust, Plymouth, Devon, England
[13] IRCCS Neuromed, Epilepsy Surg Ctr, Pozzilli, Italy
[14] Univ Hosp Bretonneau, Tours, France
[15] INSERM, U930, Tours, France
[16] Gui de Chauliac Hosp, Epilepsy Unit, CNRS, UMR 5203,U1191,INSERM, Montpellier, France
[17] Univ Hosp Marburg, Epilepsy Ctr Hessen, Marburg, Germany
[18] Hosp Univ Miguel Servet, Zaragoza, Spain
[19] Hosp Clin San Carlos, Madrid, Spain
[20] Hosp la Princesa, Madrid, Spain
来源：
EPILEPSIA | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P756
引用
收藏
页码：229 / 230
页数：2
相关论文
共 50 条
  • [41] The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn's disease
    Dignass, A. U.
    Gisbert, J. P.
    Bossa, F.
    Freudensprung, U.
    Addison, J.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I418 - I418
  • [42] The PROPER study: interim analysis of a pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn's disease
    Dignass, A.
    Gisbert, J.
    Freudensprung, U.
    Addison, J.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S459 - S460
  • [43] A Tutorial on Net Benefit Regression for Real-World Cost-Effectiveness Analysis Using Censored Data from Randomized or Observational Studies
    Chen, Shuai
    Bang, Heejung
    Hoch, Jeffrey S.
    MEDICAL DECISION MAKING, 2024, 44 (03) : 239 - 251
  • [44] The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease
    Ulf Müller-Ladner
    Axel Dignass
    Karl Gaffney
    Deepak Jadon
    Marco Matucci-Cerinic
    Triana Lobaton
    Philippe Carron
    Javier P. Gisbert
    Ira Pande
    Maximilian Utzinger
    Janet Addison
    BioDrugs, 2023, 37 : 873 - 889
  • [45] 12-month effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by etiology at baseline in the real-world: subgroup data from the international EXPERIENCE pooled analysis
    Strzelczyk, A.
    D'Souza, W.
    Faught, E.
    Klein, P.
    Reuber, M.
    Rosenow, F.
    Salas-Puig, J.
    Insuga, V. Soto
    Steinhoff, B. J.
    Szaflarski, J. P.
    Besson, H.
    Bourikas, D.
    Daniels, T.
    Floricel, F.
    Friesen, D.
    Laloyaux, C.
    Sendersky, V.
    Villanueva, V.
    EPILEPSIA, 2023, 64 : 18 - 19
  • [46] The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease
    Mueller-Ladner, Ulf
    Dignass, Axel
    Gaffney, Karl
    Jadon, Deepak
    Matucci-Cerinic, Marco
    Lobaton, Triana
    Carron, Philippe
    Gisbert, Javier P.
    Pande, Ira
    Utzinger, Maximilian
    Addison, Janet
    BIODRUGS, 2023, 37 (06) : 873 - 889
  • [47] Effectiveness and tolerability of Brivaracetam in adults with epilepsy aetiology of cerebral neoplasm, cerebrovascular accident or cranial trauma: Pooled data analyses from two real-world studies
    Dave, H.
    Sperling, M. R.
    Moseley, B.
    Elmoufti, S.
    Little, A.
    Bourikas, D.
    Steinhoff, B. J.
    EPILEPSIA, 2024, 65 : 79 - 79
  • [48] Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations
    Christopoulos, Petros
    Girard, Nicolas
    Proto, Claudia
    Soares, Marta
    Lopez, Pilar Garrido
    van der Wekken, Anthonie J.
    Popat, Sanjay
    Diels, Joris
    Schioppa, Claudio A.
    Sermon, Jan
    Rahhali, Nora
    Pick-Lauer, Corinna
    Adamczyk, Agnieszka
    Penton, James
    Wislez, Marie
    CANCERS, 2023, 15 (22)
  • [49] Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries
    Eroglu, Talip E.
    Mohr, Grimur H.
    Blom, Marieke T.
    Verkerk, Arie O.
    Souverein, Patrick C.
    Torp-Pedersen, Christian
    Folke, Fredrik
    Wissenberg, Mads
    van den Brink, Lettine
    Davis, Richard P.
    de Boer, Anthonius
    Gislason, Gunnar H.
    Tan, Hanno L.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (06) : 347 - 355
  • [50] Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups
    Yale, Jean-Francois
    Bodholdt, Ulrik
    Catarig, Andrei-Mircea
    Catrina, Sergiu
    Clark, Alice
    Ekberg, Neda Rajamand
    Erhan, Umut
    Holmes, Patrick
    Knudsen, Soren Tang
    Liutkus, Joanne
    Sathyapalan, Thozhukat
    Schultes, Bernd
    Rudofsky, Gottfried
    BMJ OPEN DIABETES RESEARCH & CARE, 2022, 10 (02)
12345